Freestone Capital Holdings
BIO icon

Freestone Capital Holdings’s Bio-Rad Laboratories Class A BIO Stock Holding History

Freestone Capital Holdings’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6
Closed -$3.5K – 467
2020
Q4 		$3.5K Hold
6
– – ﹤0.01% 1057
2020
Q3 		$3.09K Buy
+6
New +$3.04K ﹤0.01% 967

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Freestone Capital Holdings's BIO Position: Q1 2021 in Review

Freestone Capital Holdings sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2021, closing a stake of 6 shares — an estimated $3.5K sold.

Freestone Capital Holdings first reported a position in BIO in Q3 2020 and held it in 2 quarters. The position peaked at $3.5K in Q4 2020. 491 funds tracked by Wall St. Rank hold BIO as of Q1 2021.

  • Freestone Capital Holdings reported no remaining Bio-Rad Laboratories Class A position as of Q1 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 6 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $3.5K.
  • Freestone Capital Holdings first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and held it in 2 quarters.
  • Freestone Capital Holdings's Bio-Rad Laboratories Class A position peaked at $3.5K in Q4 2020.
  • 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.

Based on Freestone Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.